Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.79 |
| ▸ | HTT | P42858 | 2/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.79 |
| ▸ | PKM | P14618 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 7/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | AHR | P35869 | 1/20 | 0.60 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | SYK | P43405 | 5/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16627430 | 0.88 | MEN1 (0.81) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL7281318 | 0.88 | MEN1 (0.81) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL5079789 | 0.84 | LMNA (0.66) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL5250412 | 0.84 | LMNA (0.65) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL5083062 | 0.83 | RAB9A (0.72) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL28282946 | 0.81 | LMNA (0.73) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL9496511 | 0.80 | LMNA (1.00) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL5255345 | 0.80 | LMNA (0.71) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL28949487 | 0.80 | LMNA (0.71) | MEN1KMT2AHTTMAPK1PKM | |
| SCHEMBL29898238 | 0.80 | LMNA (0.71) | MEN1KMT2AHTTMAPK1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106061967-B | The nicotinamide compounds replaced through heteroaryl | 百时美施贵宝公司 | 2019-04-19 | — | — | CN | claimed |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | CNR2, CNR1, PDE4A | MEN1 3868/4885KMT2A 2846/4885HTT 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.